Table 3.
LAR (cancer incidence per 100,000 treated females) |
|||||||
---|---|---|---|---|---|---|---|
Organs | OMD (Gy) | Age of treatment (years) | |||||
35 | 40 | 50 | 60 | 70 | 80 | ||
Stomach | 0.582 | 392 | 380 | 344 | 289 | 210 | 111 |
Colon | 0.055 | 28 | 27 | 25 | 21 | 15 | 7 |
Liver | 0.640 | 87 | 85 | 80 | 68 | 49 | 26 |
Lung (contralateral)a | 0.223 | 384 | 380 | 361 | 316 | 240 | 140 |
Breast (contralateral) | 0.274 | 548 | 406 | 205 | 93 | 37 | 11 |
Uterus | 0.020 | 4 | 4 | 3 | 2 | 1 | 0 |
Ovary | 0.017 | 4 | 4 | 3 | 3 | 1 | 1 |
Urinary bladder | 0.021 | 11 | 11 | 10 | 9 | 7 | 4 |
Other solid cancersb | 0.055 | 117 | 110 | 92 | 69 | 44 | 20 |
Thyroid | 0.200 | 79 | 47 | 14 | 4 | 1 | 0 |
All solid cancers | – | 1654 | 1454 | 1138 | 873 | 606 | 321 |
Leukemia_1c | 0.796 | 510 | 509 | 501 | 480 | 425 | 322 |
Leukemia_2d | 0.122 | 81 | 81 | 80 | 77 | 68 | 53 |
LAR, lifetime attributable risk; OMD, mean absorbed dose at organ.
Ipsilateral lung has mean absorbed dose out of BEIR VII range (> 1.0 Gy).
Colon mean absorbed dose, according to BEIR VII methodology.
Mean absorbed dose in RBM.
Mean absorbed dose in RBM excluding absorbed doses in the ribs.